Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP-D8
- Development stage
- Preclinical
- Lead developer
- Third Military Medical University
- Modality
- Peptides
01
Overview
AP-D8 is an antagonistic peptide targeting decoy receptor 2 (DcR2). Developed by researchers at the Army Medical University in Chongqing, China, AP-D8 was screened from a phage display library as a potent antagonist of DcR2. In preclinical models of acute kidney injury (AKI), AP-D8 has been shown to inhibit renal interstitial fibrosis and tubular senescence, thereby promoting cell proliferation and regeneration. Mechanistically, DcR2 drives AKI progression and tubular senescence by suppressing Hmgcs2-mediated beta-hydroxybutyrate (β-OHB) production; by blocking DcR2, AP-D8 restores Hmgcs2 expression and β-OHB levels, alleviating kidney injury.
- Other names
- antagonistic peptide of DcR2 AP-D8
02
Targets
TNFRSF10D (TRAIL receptor 4)
Beyond the preview
Go deeper on AP-D8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP-D8.